

Third John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease

Supported by an unrestricted educational grant from United Therapeutics



7-8 March 2008, Royal Society, London, UK

Session Chairs

Professor Sheila G Haworth, CBE, London, UK

Professor Robert Naeije, Brussels, Belgium

Professor Andrew Peacock, Glasgow, UK

Professor Christoph Thiemermann, London, UK

Allocated 11 CPD credits by the Royal College of Physicians

WILLIAM HARVEY CONFERENCES

 **United
Therapeutics**
CORPORATION
REGISTREDA 1000 LSCA

7 March 2008

- 9-10am** Registration, tea and coffee
- 10am** Welcome by Professor Chris Thiemermann, FMedSci

Basic Science I: Pharmacology of Prostacyclin and New Therapeutic Approaches

Chair: Chris Thiemermann, William Harvey Research Institute, London, UK

- 10.10am** PPAR γ as a Cellular Target for Prostacyclin Analogues in PAH
Lucie Clapp, UCL, London, UK
- 10.40am** Roles of IP and PPAR- β Receptors in the Sensing of Prostacyclin in Vessels and Blood
Jane Mitchell, Imperial College, London, UK
- 11.10am** Prostacyclin Analogues and Red Blood Cell Function in Pulmonary Hypertension
Randy Sprague, St Louis University, Saint Louis, USA
- 11.40am** Molecular Genetic Basis of PAH
Richard Trembath, Kings College London, London, UK
- 12.10pm** Potential of Nitrate/Nitrite as a Vasodilator Therapy
Amrita Ahluwalia, William Harvey Research Institute, London, UK
- 12.40pm** Lunch

Clinical Science I: Clinical Developments in PAH

Chair: Sheila G Haworth, CBE, University of London, London UK

- 1.40pm** Paediatric Experience with Prostacyclins
Sheila G Haworth, CBE, Institute of Child Health, UCL, London, UK
- 2.10pm** Inhaled Prostacyclins and PAH
Lewis Rubin, University of California, San Diego, USA
- 2.40pm** Parenteral use of Treprostinil
Joanna Pepke-Zaba, Papworth Hospital, Cambridge, UK
- 3.10pm** Refreshments
- 3.30pm** Relevance of Short Term Therapeutic Studies of Clinical Management of PAH
Nazzareno Galie, University of Bologna, Bologna, Italy
- 4pm** **Debate:** Treatment Guidelines are Advancing the Management of PAH?
Moderator: Nick Ross Panel: Helder Mota-Filipe, Inframed, Lisbon, Portugal; Sheila G Haworth, CBE, London, UK; Simon Gibbs, London, UK; Nazzareno Galie, Bologna, Italy
- 5pm** Adjournment
- 7.30pm** Conference Dinner

Basic Science II: Pathophysiology and Therapy of PAH

Chair: Robert Naeije, Erasme University Hospital, Brussels, Belgium

- 9.30am** Tissue Factor Inhibitors as a Novel Therapeutic Strategy in Severe PAH
Jim White, University of Rochester Medical Center, Rochester, USA
- 10am** Extreme Altitude as a Model of Human PAH
Robert Naeije, Erasme University Hospital, Brussels, Belgium
- 10.30am** BMPR-II Signalling and PAH
Nick Morrell, University of Cambridge, Cambridge, UK
- 11am** Refreshments
- 11.20am** Therapeutic Targets within the Serotonin System
Mandy MacLean, Glasgow University, Glasgow, Scotland
- 11.50am** Imatinib Treatment for PAH
Robert Voswinckel, University of Giessen, Giessen, Germany
- 12.20pm** Lunch

Clinical Science II: Clinical Developments in PAH

Chair: Andrew Peacock, Scottish Pulmonary Vascular Unit, Glasgow, Scotland

- 1.20pm** 2008 Consensus Document from the UK PAH Treatment Centres
Simon Gibbs, Imperial College, University of London, London, UK
- 1.50pm** A Strategy for Combination Therapy in PAH
Ardeschir Ghofrani, Justus-Liebig-University Giessen, Giessen, Germany
- 2.20pm** Refreshments
- 2.50pm** MRI as a Tool to Assess PAH
Anton Vonk-Noordegraaf, VU Medical Centre, Amsterdam, Netherlands
- 3.20pm** New Imaging Techniques to Assess PAH and the RV: Echocardiography
John Sanderson, University of Birmingham, Birmingham, UK
- 3.50pm** Summary and Outlook
Andrew Peacock, Scottish Pulmonary Vascular Unit, Glasgow, Scotland
- 4.20pm** Close